Qiu Z - Search Results

1

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers.

Huang R, Qiu Z, Zheng C, Zeng R, Chen W, Wang S, Li E, Xu Y. Huang R, et al. Among authors: qiu z. Front Oncol. 2022 Apr 7;12:734581. doi: 10.3389/fonc.2022.734581. eCollection 2022. Front Oncol. 2022. PMID: 35463306 Free PMC article. Review.

2

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer.

Qiu Z, Chen Z, Zhang C, Zhong W. Qiu Z, et al. Exp Hematol Oncol. 2019 Aug 22;8:19. doi: 10.1186/s40164-019-0143-z. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 31463163 Free PMC article. Review.

3

A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer.

Tang W, Hou Q, Lin J, Li D, Lin J, Chen J, Qiu Z, Chu X, Yang X, Yan H, Wang S, Wu Y, Zhong W. Tang W, et al. Among authors: qiu z. Front Oncol. 2020 Sep 2;10:1503. doi: 10.3389/fonc.2020.01503. eCollection 2020. Front Oncol. 2020. PMID: 33014793 Free PMC article.

4

Dynamic ¹⁸ F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.

Chen ZY, Fu R, Tan XY, Yan LX, Tang WF, Qiu ZB, Qi YF, Li YF, Hou QY, Wu YL, Zhong WZ, Jiang BY. Chen ZY, et al. Thorac Cancer. 2022 Sep;13(17):2524-2531. doi: 10.1111/1759-7714.14562. Epub 2022 Jul 12. Thorac Cancer. 2022. PMID: 35822254 Free PMC article.

5

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis.

Zhang C, Chen HF, Yan S, Wu L, Yan LX, Yan XL, Yue DS, Xu CW, Zheng M, Li JS, Liu SY, Yang LL, Jiang BY, Ou QX, Qiu ZB, Shao Y, Wu YL, Zhong WZ. Zhang C, et al. NPJ Precis Oncol. 2022 Sep 19;6(1):66. doi: 10.1038/s41698-022-00301-8. NPJ Precis Oncol. 2022. PMID: 36123526 Free PMC article.

6

[No title available]

[No authors listed] [No authors listed] PMID: 37845563

7

Expression Changes in Programmed Death Ligand 1 from Precancerous Lesions to Invasive Adenocarcinoma in Subcentimeter Pulmonary Nodules: A Large Study of 2022 Cases in China.

Yang X, Xiao Y, Hu H, Qiu ZB, Qi YF, Wang MM, Wu YL, Zhong WZ. Yang X, et al. Ann Surg Oncol. 2023 Nov;30(12):7400-7411. doi: 10.1245/s10434-023-14009-x. Epub 2023 Sep 1. Ann Surg Oncol. 2023. PMID: 37658270

8

Feasibility of intraoperative assessment of STAS in pathologic stage 1 lung adenocarcinomas in Chinese patients.

Xu F, Liu Z, Yan J, Yan L, Qiu Z, Ge Y, Lv S, Zhong W. Xu F, et al. Among authors: qiu z. Eur J Surg Oncol. 2024 Oct 8:108747. doi: 10.1016/j.ejso.2024.108747. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 39428271

9

EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass Opacities.

Tang WF, Qiu ZB, Chu XP, Zeng YM, Hu YB, Tang X, Yu YF, Li WH, Zhong WZ, Huang WZ, Liang Y. Tang WF, et al. Ann Surg Oncol. 2024 Dec 25. doi: 10.1245/s10434-024-16730-7. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39722087

10

Sublobectomy for stage IA1-2 invasive lung adenocarcinoma with consolidation tumor ratio ≤ 0.25.

Qi YF, Qiu ZB, Zhang C, Fu R, Yang XW, Chu XP, Chen ZH, Yang XN, Wu YL, Zhong WZ. Qi YF, et al. Thorac Cancer. 2022 Nov;13(22):3174-3182. doi: 10.1111/1759-7714.14672. Epub 2022 Oct 8. Thorac Cancer. 2022. PMID: 36208139 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,237 results

Search Page

Filters